other material
confidence high
sentiment neutral
materiality 0.50
Arcadia shareholders approve reverse stock split, 2026 equity plan, and director election
Arcadia Biosciences, Inc.
- Gregory D. Waller elected Class II director with 377,954 for, 105,236 withheld; 776,125 broker non-votes.
- Approved reverse stock split at 1-for-2 to 1-for-10 ratio, board discretion, action required before June 30, 2027.
- 2026 Omnibus Equity Incentive Plan approved; 400,000 shares initial limit, annual 4% reserve increase from Jan 1, 2027.
- Approved issuance of shares upon exercise of Series A-1 Preferred Investment Options from June 12, 2026 private placement.
- Advisory say-on-pay passed; Ramirez Jimenez International CPAs ratified as independent auditor for FY 2026.